StockData
Intensity Therapeutics, Inc. logo

Intensity Therapeutics, Inc. (INTS) stock

INTSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$3.08−0.02 (-0.65%)

Close on Nov 13, 2026Market cap $10.06MP/E –Yield –

Intensity Therapeutics gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

No gross profit figures for Intensity Therapeutics

Intensity Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Intensity Therapeutics figures

See a number that looks wrong?